F. Lalezari

发表

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

H. Aerts, C. Parmar, C. Swanton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study

L. Beenen, H. Büller, A. Maraveyas, 2018 .

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

S. Baylin, R. Scharpf, D. Ettinger, 2020, Nature Cancer.

Angioplasty with or without stent placement in the brachiocephalic artery: feasible and durable? A retrospective cohort study.

F. Moll, F. Lalezari, J. D. de Vries, 2007, Journal of vascular and interventional radiology : JVIR.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

J. Aerts, P. Baas, V. van der Noort, 2019, JAMA oncology.

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

E. Thunnissen, P. Baas, H. Klomp, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.

H. Groen, J. Aerts, G. Bootsma, 2021, The Lancet. Respiratory medicine.

Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

H. Horlings, T. Schumacher, S. Linn, 2018 .

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)

A. Broeks, K. Sikorska, E. Rozeman, 2019, Melanoma research.

PD-1 T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in 1 patients with advanced NSCLC 2

A. Broeks, T. Schumacher, K. Mertz, 2022 .

Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practice

E. Cuppen, E. de Bruijn, G. Meijer, 2022, The Journal of pathology.

The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases.

A. Aalbers, B. van Ramshorst, F. Lalezari, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

W. V. van Harten, T. Schumacher, J. Beijnen, 2022, The New England journal of medicine.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

H. Horlings, L. Wessels, T. Schumacher, 2019, Nature Medicine.

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.

P. Baas, V. van der Noort, K. Monkhorst, 2019, The Lancet. Respiratory medicine.

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience

E. Rozeman, C. Blank, J. Haanen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

H. Horlings, T. Schumacher, L. Wessels, 2019, Nature Medicine.

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

E. Cuppen, P. Roepman, A. J. van den Broek, 2022, ESMO open.

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

J. Schellens, M. Verheij, D. Pluim, 2020, Clinical Cancer Research.

Unilateral thymus displacement.

F. Lalezari, F. Beek, H. Brouwers, 2009, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie.

Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer

J. V. van Sandick, B. Aleman, Jeffrey D. Steinberg, 2018, Strahlentherapie und Onkologie.

LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

I. Svane, J. Haanen, Ö. Met, 2022, Annals of Oncology.

18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): results from a randomised clinical trial.

J. Sonke, W. V. van Elmpt, K. Sikorska, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

H. Horlings, L. Wessels, S. Linn, 2019, Nature Medicine.

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

C. Blank, J. Haanen, T. Powles, 2022, European Urology Open Science.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

H. Horlings, T. Schumacher, L. Wessels, 2019, Nature Network Boston.